Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 3, 2010, Pages 613-625

  Friel, Anne M ^a   Corcoran, Claire ^a   Crown, John ^a   O'Driscoll, Lorraine ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast cancer; Cancer stem cells; Circulating tumor cells; Exosomes; Extracellular nucleic acids

Indexed keywords

BIOLOGICAL MARKER; BMI1 PROTEIN; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLIN D1; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXTRACELLULAR DNA; EXTRACELLULAR NUCLEIC ACID; EXTRACELLULAR RNA; MAMMAGLOBIN; MICRORNA; NUCLEIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB; UNCLASSIFIED DRUG; UROKINASE; MESSENGER RNA; TUMOR MARKER;

BREAST BIOPSY; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CELL ASSAY; CIRCULATING TUMOR CELL; EXOSOME; GENE EXPRESSION; HUMAN; MAMMOGRAPHY; METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; BLOOD; BREAST TUMOR; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TUMOR EMBOLISM;

ANIMALS; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; EXOSOMES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MICRORNAS; NEOPLASTIC CELLS, CIRCULATING; NUCLEIC ACIDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 78951475136     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0980-2     Document Type: Review

References (157)

1. Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96 (Pubitemid 351521864)
2. Perou C et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
3. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790-800
4. Jiang WG et al (2002) Molecular detection of micro-metastasis in breast cancer. Crit Rev Oncol Hematol 43(1):13-31 (Pubitemid 34722785)
5. Gilbey AM et al (2004) The detection of circulating breast cancer cells in blood. J Clin Pathol 57(9):903-911 (Pubitemid 39208239)
6. Pantel K, Brakenhoff R (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448-456 (Pubitemid 38745530)
7. Al-Hajj M et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-3988 (Pubitemid 36418143)
8. Zhang S et al (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68(11):4311-4320
9. Baba T et al (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133? ovarian cancer cells. Oncogene 28(2):209-218
10. Curley M et al (2009) CD133 Expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27(12):2875-2883
11. Rutella S et al (2009) Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 15(13):4299-4311
12. Ashworth T (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146-147
13. Allan AL, Keeney M (2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010:426218
14. Liu M et al (2009) Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27(31):5153-5159
15. Cristofanilli M et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781-791 (Pubitemid 39095313)
16. Budd G et al (2006) Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12(21):6403-6409 (Pubitemid 44799711)
17. Hayes D et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(141):4218-4224
18. Pierga J et al (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14(21):7004-7010
19. Harris L et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-5312 (Pubitemid 350232263)
20. Nagrath S et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173): 1235-1239
21. Tewes M et al (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: An option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115(3):581-590
22. Alix-Panabiéres C et al (2005) Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 299(1-2): 177-188 (Pubitemid 40725934)
23. Alix-Panabiéres C et al (2007) Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53(3):537-539 (Pubitemid 46447957)
24. Fehm T et al (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11(4):R59
25. Fehm T et al (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9(5):R74
26. Alunni-Fabbroni M, Sandri M (2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50(4):289-297
27. Vona G et al (2000) Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156(1): 57-63 (Pubitemid 30644439)
28. Gertler R et al (2003) Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 162:149-155
29. Müller V et al (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11(10):3678-3685 (Pubitemid 40685584)
30. Naume B et al (2004) Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 6(3):244-252 (Pubitemid 38868097)
31. Hayes G et al (2010) Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. Leuk Res 34(6):809-815
32. Mostert B et al (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35(5):463-474
33. Cristofanilli M, Braun S (2010) Circulating tumor cells revisited. JAMA 303(11):1092-1093
34. Fehm T et al (2005) Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7(2):171-185 (Pubitemid 40872753)
35. Austrup F et al (2000) Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer 83(12):1664-1673 (Pubitemid 32001712)
36. Fehm T et al (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8(7):2073-2084 (Pubitemid 34753576)
37. Meng S et al (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103(46):17361-17365 (Pubitemid 44788974)
38. Meng S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101(25): 9393-9398 (Pubitemid 38812885)
39. Pantel K et al (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329-340 (Pubitemid 351596394)
40. Braun S et al (2009) The prognostic impact of bone marrow micrometastases in women with breast cancer. Cancer Invest 27(6):598-603
41. Braun S et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793-802 (Pubitemid 41215488)
42. Janni W et al (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103(5):884-891 (Pubitemid 40270064)
43. Krawczyk N et al (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29(10):4019-4024
44. Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguine chez l'homme (in French). C R Seances Soc Biol Fil 142(3-4):241-243
45. Tan EM et al (1966) Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45(11):1732-1740
46. Koffler D et al (1973) The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52(1):198-204
47. Leon S et al (1977) Free DNA in the serum of rheumatoid arthritis patients. J Rheumatol 4(2):139-143
48. Leon S et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646-650 (Pubitemid 8051621)
49. Stroun M et al (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46(5):318-322 (Pubitemid 19216753)
50. Sorenson G et al (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 3(1):67-71
51. Vasioukhin V et al (1994) Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 86(4):774-779 (Pubitemid 24194434)
52. Kohler C et al (2009) Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 8:105
53. Divella R et al (2009) Circulating hTERT DNA in early breast cancer. Anticancer Res 29(7):2845-2849
54. Van der Auwera I et al (2009) The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 100(8):1277-1286
55. van der Drift M et al (2010) Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68(2):283-287
56. Yoon K et al (2009) Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 11(3):182-185
57. Yen L et al (2009) Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15(13):4508-4513
58. Ellinger J et al (2009) CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol 182(1):324-329
59. Board R et al (2009) Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 101(10):1724-1730
60. Chuang T et al (2010) Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 32(2):229-234
61. Schwarzenbach H et al (2009) Comparative evaluation of cellfree tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 11(5):R71
62. Marrakchi R et al (2008) Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer. Int J Biol Markers 23(4):238-243
63. García V et al (2008) Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 263(2):312-320
64. O'Driscoll L et al (2008) Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics 5(2):94-104
65. Terrin L et al (2008) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 14(22):7444-7451
66. Vrieling A et al (2009) Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. Growth Horm IGF Res 19(2):126-135
67. Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer-A survey. Biochim Biophys Acta 1775(1):181-232 (Pubitemid 44911084)
68. Rieber M, Bacalao J (1974) An ''external'' RNA removable from mammalian cells by mild proteolysis. Proc Natl Acad Sci USA 71(12):4960-4964
69. Laktionov PP et al (2004) Cell-surface-bound nucleic acids: free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients. Ann NY Acad Sci 1022:221-227 (Pubitemid 38951606)
70. Chelobanov BP et al (2004) Isolation of nucleic acid binding proteins: An approach for isolation of cell surface, nucleic acid binding proteins. Ann NY Acad Sci 1022:239-243 (Pubitemid 38951609)
71. Wieczorek AJ, Rhyner K (1989) A gene probe test for serum RNA proteolipid in neoplasia. Schweiz Med Wochenschr 119(39):1342-1343 (Pubitemid 19240958)
72. Wieczorek AJ et al (1985) Isolation and characterization of an RNA-proteolipid complex associated with the malignant state in humans. Proc Natl Acad Sci USA 82(10):3455-3459 (Pubitemid 15030702)
73. Hasselmann DO et al (2001) Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 47(8):1488-1489 (Pubitemid 32678837)
74. Stroun M et al (1978) Presence of RNA in the nucleoprotein complex spontaneously released by human lymphocytes and frog auricles in culture. Cancer Res 38(10):3546-3554 (Pubitemid 9043248)
75. Jachertz D et al (1979) Information carried by the DNA released by antigen-stimulated lymphocytes. Immunology 37(4):753-763 (Pubitemid 10220695)
76. Anker P et al (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18(1):65-73 (Pubitemid 29411092)
77. Jahr JS et al (2001) A novel approach to measuring circulating blood volume: the use of a hemoglobin-based oxygen carrier in a rabbit model. Anesth Analg 92(3):609-614 (Pubitemid 32185098)
78. Skog J et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470-1476
79. Wright LC et al (1986) A proteolipid in cancer cells is the origin of their high-resolution NMR spectrum. FEBS Lett 203(2): 164-168 (Pubitemid 16046792)
80. Rosi A et al (1988) RNA-lipid complexes released from the plasma membrane of human colon carcinoma cells. Cancer Lett 39(2):153-160
81. Ceccarini M et al (1989) Biochemical and NMR studies on structure and release conditions of RNA-containing vesicles shed by human colon adenocarcinoma cells. Int J Cancer 44(4):714-721 (Pubitemid 19258750)
82. Ratajczak J et al (2006) Membrane-derived microvesicles: important and underappreciated mediators of cell-To-cell communication. Leukemia 20(9):1487-1495 (Pubitemid 44264090)
83. Graner MW et al (2009) Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 23(5):1541-1557
84. Thery C et al (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2(8):569-579 (Pubitemid 37328732)
85. Keller S et al (2006) Exosomes: from biogenesis and secretion to biological function. Immunol Lett 107(2):102-108 (Pubitemid 44779821)
86. Calzolari A et al (2006) TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119(Pt 21):4486-4498 (Pubitemid 44830648)
87. Valadi H et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654-659 (Pubitemid 47214727)
88. Safaei R et al (2005) Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4(10):1595-1604 (Pubitemid 41556443)
89. Chaput N et al (2005) The potential of exosomes in immunotherapy. Expert Opin Biol Ther 5(6):737-747 (Pubitemid 40873883)
90. Liu C et al (2006) Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 176(3):1375-1385 (Pubitemid 43134279)
91. Ginestra A et al (1998) The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 18(5A):3433-3437 (Pubitemid 28546471)
92. Clayton A et al (2007) Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67(15):7458-7466 (Pubitemid 47214451)
93. Ng EK et al (2002) Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 48(8):1212-1217 (Pubitemid 34809828)
94. O'Driscoll L (2007) Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. Anticancer Res 27(3):1257-1265 (Pubitemid 46807271)
95. Rabinowits G et al (2009) Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer 10(1):42-46
96. Silva JM et al (2001) Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 7(9):2821-2825 (Pubitemid 32911391)
97. Chen X et al (2000) Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 6(10):3823-3826
98. Silva J et al (2007) Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 9(4):R55
99. Fuchs E, Weber K (1994) Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63:345-382
100. Dohmoto K et al (2001) The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer 91(4):468-473 (Pubitemid 32115099)
101. Pujol JL et al (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53(1):61-66
102. Ravdin PM et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980-991 (Pubitemid 32176272)
103. Stathopoulou A et al (2002) Molecular detection of cytokeratin-19- positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20(16):3404-3412
104. Xenidis N et al (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-Time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24(23):3756-3762 (Pubitemid 46622314)
105. Daskalaki A et al (2009) Detection of cytokeratin-19 mRNApositive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 101(4):589-597
106. Xenidis N et al (2003) Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14(6):849-855 (Pubitemid 36827199)
107. Quintela-Fandino M et al (2006) Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 24(22):3611-3618 (Pubitemid 46630534)
108. Wiedswang G et al (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10(16): 5342-5348 (Pubitemid 39100469)
109. Ignatiadis M et al (2008) Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 20(1):55-60
110. Alix-Panabieres C et al (2009) Full-length cytokeratin-19 is released by human tumor cells: A potential role in metastatic progression of breast cancer. Breast Cancer Res 11(3):R39
111. DePinho R (2000) The age of cancer. Nature 408(6809): 248-254
112. Dasí F et al (2006) Real-Time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann NY Acad Sci 1075:204-210 (Pubitemid 44532786)
113. Li H et al (2009) Relationship between the expression of hTERT and EYA4 mRNA in peripheral blood mononuclear cells with the progressive stages of carcinogenesis of the esophagus. J Exp Clin Cancer Res 28:145
114. Elder E et al (2003) KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16(3):246-255 (Pubitemid 36337431)
115. Shen C et al (2009) The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-Time PCR. Clin Biochem 42(3): 194-200
116. Jacobs JJ, van Lohuizen M (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602(2):151-161 (Pubitemid 34521793)
117. Raaphorst FM (2005) Deregulated expression of Polycombgroup oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 14 Spec No 1, R93-R100 (Pubitemid 40542625)
118. Song LB et al (2009) The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119(12):3626-3636
119. Bachmann IM et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268-273 (Pubitemid 46622055)
120. Kleer CG et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100(20):11606-11611 (Pubitemid 37205983)
121. van Lohuizen M et al (1991) Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65(5):737-752 (Pubitemid 121001306)
122. Liu S et al (2006) Hedgehog signaling and Bmi-1 regulate selfrenewal of normal and malignant human mammary stem cells. Cancer Res 66(12):6063-6071
123. Kim JH et al (2004) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13(5):383-388 (Pubitemid 39549787)
124. Vonlanthen S et al (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84(10):1372-1376 (Pubitemid 32522106)
125. Kim JH et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203(2):217-224 (Pubitemid 38058689)
126. Klug J et al (2000) Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report. Ann NY Acad Sci 923:348-354 (Pubitemid 32050234)
127. Ni J et al (2000) All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Ann NY Acad Sci 923:25-42 (Pubitemid 32050853)
128. Watson MA, Fleming TP (1994) Isolation of differentially expressed sequence tags from human breast cancer. Cancer Res 54(17):4598-4602 (Pubitemid 24276479)
129. Watson MA et al (1998) Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. Oncogene 16(6):817-824 (Pubitemid 28076094)
130. Tassi RA et al (2008) Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer 18(5):1090-1096
131. Watson MA, Fleming TP (1996) Mammaglobin, a mammaryspecific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 56(4):860-865 (Pubitemid 26055478)
132. Zafrakas M et al (2006) Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their coexpression in gynecologic malignancies. BMC Cancer 6:88
133. Nunez-Villar MJ et al (2003) Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 5(3):R65-R70
134. Fleming TP, Watson MA (2000) Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann NY Acad Sci 923:78-89 (Pubitemid 32050207)
135. Fanger GR et al (2002) Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol 23(4):212-221 (Pubitemid 36091916)
136. Zach O et al (1999) Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 17(7):2015-2019 (Pubitemid 29318829)
137. Cerveira N et al (2004) Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. Int J Cancer 108(4):592-595 (Pubitemid 38036661)
138. Marques AR et al (2009) Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat 114(2):223-232
139. Mikhitarian K et al (2008) Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer 8:55
140. Fu M et al (2004) Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145(12):5439-5447 (Pubitemid 39564581)
141. Butt AJ et al (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12(Suppl 1): S47-S59 (Pubitemid 41395413)
142. Carney WP et al (2004) Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 5(2):105-116 (Pubitemid 39029201)
143. Apostolaki S et al (2009) Detection of occult HER2 mRNApositive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 117(3):525-534
144. Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350-355 (Pubitemid 39265675)
145. Hennessy E, O'Driscoll L (2008) Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Rev Mol Med 10:e24
146. Gartel A, Kandel E (2008) miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol 18(2):103-110
147. Lawrie C et al (2008) Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large Bcell lymphoma. Br J Haematol 141(5):672-675 (Pubitemid 351667616)
148. Mitchell P et al (2008) Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513-10518
149. Chen X et al (2008) Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997-1006
150. Taylor D, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110(1):13-21 (Pubitemid 351853251)
151. Heneghan H et al (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251(3):499-505
152. Duffy M (2005) Predictive markers in breast and other cancers: A review. Clin Chem 51(3):494-503 (Pubitemid 40300223)
153. Gasparini G et al (2006) Is tailored therapy feasible in oncology? Crit Rev Oncol Hematol 57(1):79-101 (Pubitemid 41804082)
154. Hayes D (2005) Prognostic and predictive factors for breast cancer: translating technology to oncology. J Clin Oncol 23(8):1596-1597 (Pubitemid 46211406)
155. McShane L et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067-9072
156. Barker AD et al (2009) I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86(1):97-100
157. Pepe MS et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054-1061 (Pubitemid 32717537)